Literature DB >> 21517967

Prevalence of gastroesophageal reflux disease in a general population in Taiwan.

Li-Ju Hung1, Ping-I Hsu, Chun-Yuh Yang, E-Ming Wang, Kwok-Hung Lai.   

Abstract

BACKGROUND AND AIM: To evaluate the prevalence and risk factors of gastroesophageal reflux disease (GERD) in a general population in Taiwan.
METHODS: A validated symptom questionnaire, the Chinese GERD questionnaire, was utilized to determine the prevalence of GERD within a community in Taiwan. A cut-off value for GERD diagnosis was a total score ≥ 12. Additionally, demographic data, including sex, age, body mass index, and consumption of tobacco and alcohol, were recorded, and a logistic regression analysis was conducted to search the independent risk factors for the development of GERD in a general population.
RESULTS: In total, 1238 residents were recruited for this study. The monthly frequencies of heartburn, epigastric acidic discomfort, and acid regurgitation were 4.4%, 3.7%, and 2.9%, respectively. The GERD prevalence was 25% in the community. The multivariate analysis showed that female sex and age of 40-49 years and 50-59 years were independent risk factors related to the development of GERD, with odd ratios of 1.71, 3.65, and 2.41, respectively (95% confidence intervals: 1.26-2.34, 1.62-8.21, and 1.11-2.54, respectively).
CONCLUSIONS: GERD has become a common disorder in the general population in Taiwan. Female sex and age of 40-49 years and 50-59 years are risk factors for the development of GERD within a community.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21517967     DOI: 10.1111/j.1440-1746.2011.06750.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

Review 1.  Gastroesophageal reflux disease and non-esophageal cancer.

Authors:  Fernando A M Herbella; Sebastião Pannocchia Neto; Ilka Lopes Santoro; Licia Caldas Figueiredo
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

2.  Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.

Authors:  Kwang Jae Lee; Byoung Kwan Son; Gwang Ha Kim; Hye-Kyung Jung; Hwoon-Yong Jung; Il-Kwun Chung; In-Kyung Sung; Jin Il Kim; Jong Hyeok Kim; Joon Seong Lee; Joong Goo Kwon; Jung Ho Park; Kyu Chan Huh; Kyung Sik Park; Moo-In Park; Nayoung Kim; Oh Young Lee; Sam Ryong Jee; Sang Kil Lee; Sei Jin Youn; Sung Kook Kim; Soo Teik Lee; Su Jin Hong; Suck Chei Choi; Tae Nyeun Kim; Young Hoon Youn; Hyo Ju Park; Min Ja Kang; Chi Hye Park; Bong Tae Kim; Sangjun Youn; Geun Seog Song; Poong-Lyul Rhee
Journal:  Aliment Pharmacol Ther       Date:  2019-03-06       Impact factor: 8.171

3.  The role of tea and coffee in the development of gastroesophageal reflux disease.

Authors:  Tao-Yang Wei; Pang-Hsin Hsueh; Shu-Hui Wen; Chien-Lin Chen; Chia-Chi Wang
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2019 Jul-Sep

4.  Higher Dementia Risk in People With Gastroesophageal Reflux Disease: A Real-World Evidence.

Authors:  Shuo-Yan Gau; Jung-Nien Lai; Hei-Tung Yip; Meng-Che Wu; James Cheng-Chung Wei
Journal:  Front Aging Neurosci       Date:  2022-04-04       Impact factor: 5.750

5.  Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.

Authors:  Chia-Han Lee; Mei-Chiou Shen; Ming-Ju Tsai; Jung-San Chang; Yaw-Bin Huang; Yi-Hsin Yang; Kun-Pin Hsieh
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

6.  Clinical Benefits and Challenges in Application of Novel Portable Gastric Capsule Endoscopy for Home Healthcare Patients.

Authors:  Yang-Chao Lin; Ching-Lin Chen; Yi-Wei Kao; Ching-Yao Tsai; Mingchih Chen; Chih-Kuang Liu
Journal:  Diagnostics (Basel)       Date:  2022-07-20

7.  Antireflux endoluminal therapies: past and present.

Authors:  Kuo Chao Yew; Seng-Kee Chuah
Journal:  Gastroenterol Res Pract       Date:  2013-07-09       Impact factor: 2.260

8.  Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.

Authors:  Seung Han Kim; Kwang Bum Cho; Hoon Jai Chun; Sang Woo Lee; Joong Goo Kwon; Dong Ho Lee; Sang Gyun Kim; Hwoon-Yong Jung; Ji Won Kim; Joon Seong Lee; Hyojin Park; Suck Chei Choi; Sam Ryong Jee; Hyun-Soo Kim; Kwang Hyun Ko; Seun Ja Park; Yong Chan Lee; Soo Heon Park; Ah Rong Kim; Eun Ji Kim; Hyun Wook Park; Bong Tae Kim; Geun Seog Song
Journal:  Aliment Pharmacol Ther       Date:  2021-07-06       Impact factor: 8.171

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.